SEC For	m 4																
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STAT		iled pu	NT OF CHANGES IN BENEFICIAL OWN d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							ERSHIP		OMB Number: 3235-02 Estimated average burden		3235-0287
transac contrac the pur securiti to satis	chase or sale or es of the issue fy the affirmation ons of Rule 10t	pursuant to a written plan for of equity r that is intended ve defense															
1. Name ar <u>Boylan</u>				2. Issuer Name <b>and</b> Ticker or Tradi Zenas BioPharma, Inc.							Relationship o eck all applica	able)	eporting Person(s) to Issuer e) 10% Owner				
	C/O ZENAS BIOPHARMA, INC.			(Middle)			of Earliest T 2024	ransa	action (Month	h/Day/Year)			Officer ( below)	(give title	tle Other (specify below)		specify
1000 WINTER ST., SUITE 1200					4.	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Jo Line)								oint/Group	Filing	(Check App	olicable
(Street) WALTHAM MA			02451										Form fil	ed by Mor	d by One Reporting Person d by More than One Reporti		
(City) (State)		(Zip)															
		Та	ble I - Nor	-Deri	vativ	/e Se	curities	Aco	quired, Di	sposed of	f, or Ben	eficial	y Owned				
1. Title of Security (Instr. 3)				2. Tran Date (Month		Year)	2A. Deemed Execution Date, if any (Month/Day/Year		3. Transactic Code (Inst ) 8)			d (A) or r. 3, 4 and	4 and Securities Beneficial Owned Fo		Form (D) or	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code V	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)
			Table II -							oosed of, convertib			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, 1	4. Fransa Code ( 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/	ate	7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivativ Securitie Beneficia Owned Following Reported Transact	e s ally g	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
				Code	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$17	09/12/2024			А		37,000 <sup>(1)</sup>		(2)	09/11/2034	Common Stock	37,000	\$0	37,00	)0	D	
Explanatio	n of Respons	ses:						_									

1. Mr. Boylan has agreed to receive and hold for the benefit of, Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.

2. The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service.

## By: /s/ Chase Jayasekera, Attorney-in-Fact

\*\* Signature of Reporting Person Date

09/16/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.